Catalent Pharma Solutions, a Somerset, New Jersey-based firm with a manufacturing facility in Madison, has entered into a manufacturing agreement with Xenetic Biosciences, which will include cGMP manufacturing for Xenetic’s recombinant protein, Human DNase I. According to a joint release, Vikalp Mohan, global vice president, and head of drug substance at Catalent Biologics, said the biomanufacturing for the partnership will take place at the Madison site. Xenetic’s interventional DNase-based oncology platform is aimed at improving the outcomes of existing treatments, including immunotherapies.
Get Our Email Newsletter
The companies, people and issues shaping business in Madison and the Capital Region.
